Market Place
Sourcing Support
Dr Reddy`s Generic Midostaurin Receives Approval in US
28 Jun 2024 //
FDA
Lotus`s Generic Midostaurin Receives Approval in the U.S.
24 Aug 2022 //
FDA
Actinium Evaluates Primary Endpoint of Pivotal Phase 3 SIERRA Trial
13 Dec 2021 //
PRNEWSWIRE
NICE Recommends First Treatment for Rare Blood Disorder
20 Aug 2021 //
GLOBALGENES
NICE recommends first treatment for rare blood disorder
19 Aug 2021 //
NICE
Blueprint challenges Novartis with new Ayvakit nod
18 Jun 2021 //
FIERCEPHARMA
Astellas` AML drug wins over CHMP — strengthening lead on Daiichi Sankyo
20 Sep 2019 //
ENDPTS
FDA Issues 54 New and Revised Product-Specific Guidances
13 Sep 2018 //
RAPS
As NDA talks loom, FDA hands Daiichi Sankyo breakthrough on quizartinib
02 Aug 2018 //
ENDPTS
Prescription med: registration of new chemical entities in Australia
09 Jul 2018 //
TGA
Daiichi Sankyo in pursuit of Novartis’ Rydapt with next-generation FLT3 drug
10 May 2018 //
FIERCE BIOTECH
NICE OKs three new therapies for blood cancer
08 May 2018 //
PARMA TIMES
NICE says ‘no’ to Novartis’ AML drug Rydapt
07 Dec 2017 //
PHARMA TIMES
NICE issues early `no` on RoActemra, Rydapt
06 Dec 2017 //
FIERCE PHARMA
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.